{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:24:45Z","timestamp":1788279885560,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejphar.2026.179218","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:31:26Z","timestamp":1786084286000},"page":"179218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preclinical evaluation of itraconazole in docetaxel-resistant prostate cancer xenograft models"],"prefix":"10.1016","volume":"1032","author":[{"given":"Luciano O.","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-1214","authenticated-orcid":false,"given":"Jos\u00e9 M.A.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179218_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2026.179218_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179218_bib3","article-title":"Preclinical and clinical research models of prostate cancer: a brief overview","volume":"12","author":"Basak","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ejphar.2026.179218_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179218_bib5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1078-0432.CCR-06-2362","article-title":"A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man","volume":"13","author":"Bradshaw-Pierce","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179218_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.179218_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001599","article-title":"Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma","volume":"2","author":"Buonamici","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.179218_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1423-0127-18-6","article-title":"Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model","volume":"18","author":"Chang","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2026.179218_bib9","first-page":"625","article-title":"Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer","volume":"53","author":"Chen","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejphar.2026.179218_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejphar.2026.179218_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.179218_bib12","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.179218_bib13","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1210\/en.2004-0079","article-title":"Hedgehog signaling promotes prostate xenograft tumor growth","volume":"145","author":"Fan","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2026.179218_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review","volume":"87","author":"Francini","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2026.179218_bib15","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/annonc\/mdq050","article-title":"Docetaxel-based combination therapy for castration-resistant prostate cancer","volume":"21","author":"Galsky","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2026.179218_bib16","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.3390\/ijms140713979","article-title":"Hedgehog signaling in prostate cancer and its therapeutic implication","volume":"14","author":"Gonnissen","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179218_bib17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12885-019-5907-7","article-title":"The design, analysis and application of mouse clinical trials in oncology drug development","volume":"19","author":"Guo","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2026.179218_bib18","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ejca.2008.04.005","article-title":"When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?","volume":"44","author":"Hamberg","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179218_bib19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2026.179218_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature02962","article-title":"Hedgehog signalling in prostate regeneration, neoplasia and metastasis","volume":"431","author":"Karhadkar","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179218_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","article-title":"Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth","volume":"17","author":"Kim","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2026.179218_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ejphar.2026.179218_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061290","article-title":"Molecular profiling of docetaxel-resistant prostate cancer cells identifies multiple mechanisms of therapeutic resistance","volume":"13","author":"Lima","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.179218_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.869461","article-title":"Itraconazole reverts ABCB1-Mediated docetaxel resistance in prostate cancer","volume":"13","author":"Lima","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179218_bib25","doi-asserted-by":"crossref","first-page":"50902","DOI":"10.1074\/jbc.M300676200","article-title":"Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase\/Akt pathway in prostate cancer LNCaP cells with different passage numbers","volume":"278","author":"Lin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.179218_bib26","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.ejphar.2026.179218_bib27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00280-016-3191-7","article-title":"Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer","volume":"78","author":"Maughan","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179218_bib28","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.18632\/oncotarget.2932","article-title":"Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer","volume":"6","author":"Mimeault","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.179218_bib29","article-title":"The metastatic cascade through the lens of therapeutic inhibition","volume":"6","author":"Miranda","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejphar.2026.179218_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010074","article-title":"Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells","volume":"8","author":"Namekawa","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.179218_bib31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","article-title":"Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells","volume":"8","author":"Nanayakkara","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179218_bib32","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179218_bib33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3332\/ecancer.2015.521","article-title":"Repurposing drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent","volume":"9","author":"Pantziarka","year":"2015","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.ejphar.2026.179218_bib34","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179218_bib35","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3892\/ol.2017.6569","article-title":"Repurposing itraconazole for the treatment of cancer","volume":"14","author":"Pounds","year":"2017","journal-title":"Oncol. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.179218_bib36","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","article-title":"Making sense of itraconazole pharmacokinetics","volume":"56","author":"Prentice","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2026.179218_bib37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2026.179218_bib38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.179218_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41419-024-06949-3","article-title":"Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer","volume":"15","author":"Sarwar","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.179218_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.179218_bib41","first-page":"676","article-title":"Molecular mechanisms of docetaxel resistance in prostate cancer","volume":"3","author":"Sekino","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejphar.2026.179218_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13346-024-01592-z","article-title":"Quality by design empowered preparation of itraconazole albumin nanoparticles for prostate cancer","volume":"15","author":"Shah","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejphar.2026.179218_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.162","article-title":"Survival outcomes based on line of therapy and treatment trends with cabazitaxel in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Srivastava","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.ejphar.2026.179218_bib44","doi-asserted-by":"crossref","first-page":"vii91","DOI":"10.1093\/annonc\/mdn473","article-title":"Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer","volume":"19","author":"Sternberg","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2026.179218_bib45","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179218_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179218_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.179218_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100384","article-title":"Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants","volume":"38","author":"Yamaguchi","year":"2021","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2026.179218_bib49","doi-asserted-by":"crossref","first-page":"9143","DOI":"10.1038\/s41598-020-65767-7","article-title":"Statistical analysis of longitudinal data on tumour growth in mice experiments","volume":"10","author":"Zavrakidis","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179218_bib50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MOU.0b013e32835e2253","article-title":"Castrate-resistant prostate cancer: Postdocetaxel management","volume":"23","author":"Zhao","year":"2013","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.ejphar.2026.179218_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/medsci14010055","article-title":"Repurposing itraconazole in combination with chemotherapy and immune checkpoint inhibitor for cancer","volume":"14","author":"Zonfa","year":"2026","journal-title":"Med. Sci."},{"key":"10.1016\/j.ejphar.2026.179218_bib52","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14737140.2016.1241148","article-title":"Therapeutic management of bone metastasis in prostate cancer: an update","volume":"16","author":"Zustovich","year":"2016","journal-title":"Expert Rev. Anticancer Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:59:26Z","timestamp":1788278366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926007004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S0014299926007004"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179218","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of itraconazole in docetaxel-resistant prostate cancer xenograft models","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"179218"}}